Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:08 AM
Ignite Modification Date:
2025-12-25 @ 2:08 AM
NCT ID:
NCT04671160
Eligibility Criteria:
Inclusion Criteria:
* All adult Intensive Care Unit patients between 18 and 80 years old requiring treatment with CVVHDF;
* Indications for anticoagulant prophylaxis with enoxaparin 40 mg sc. once daily or fondaparinux 2.5 mg sc. once daily;
* Treatment with continuous veno-venous hemodiafiltration.
Exclusion Criteria:
* Indications for low molecular weight heparin use other than anticoagulant prophylaxis;
* Intracranial hemorrhage;
* Incident of serious bleeding within a week before admission to ICU, if not managed;
* Disseminated intravascular coagulopathy;
* Heparin induced thrombocytopenia;
* Hypersensitivity or allergic reaction to enoxaparin or fondaparinux;
* Thrombocytopenia \< 50 G/L;
* Prothrombin time \< 20% or INR (international normalized ratio) \> 1.7;
* Use of antiplatelet drugs;
* Presence of congenital coagulopathy.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT04671160
Study Brief:
Protocol Section:
NCT04671160